Table 6.
Immunoassays used in selected papers to detected HPV-specific antibodies in CVS.
| Detection method | Studies | Cervical HPV-specific antibodies detected (reported antibody class) |
|---|---|---|
| Neutralizing assays | ||
| SEAP-NA | Kemp et al. (2008a) [27] | nAb-HPV16/18 |
| Kemp et al. (2008b) [53] | nAb-HPV16 V5 mouse | |
| Mbulawa et al. (2008) [31] | nAb-HPV16 (IgG/A) | |
| PBNA | Einstein et al. (2009/2014) [47,49] | nAb -HPV16/18 |
| Huo et al. (2012) [52] | nAb-HPV16 | |
| Draper et al. (2013) [46] | nAb-HPV31/45 | |
| VLP-based assays | ||
| HPV VLP ELISA | Nardelli-Haefliger et al. (2003) [55] | anti-HPV16 (IgG) |
| Fife et al. (2004) [50] | anti-HPV11/16 (IgG/A) | |
| Nardelli-Haefliger et al. (2005) | anti-HPV16 (sIgA, IgG/A) | |
| Kemp et al. (2008a) | anti-HPV16/18 (IgG) | |
| Einstein et al. (2009/2011/2014) | anti-HPV16/18 (IgG) | |
| Petäjä et al. (2011) | anti-HPV16/18 (IgG) | |
| Rocha-Zavaleta et al. (2003) | anti-HPV16 (sIgA/G) | |
| Passmore et al. (2007) | anti-HPV16 (IgG/A) | |
| Mbulawa et al. (2008) | anti-HPV16 (IgG/A) | |
| Huo et al. (2012) | anti-HPV6/16/18 (IgG/A) | |
| Draper et al. (2013) | anti-HPV16/18/31/45 | |
| Schwarz et al. (2009/2010/2015/2017) | anti-HPV16/18 (IgG) | |
| Monroy et al. (2010) | anti-HPV16/18 (IgA) | |
| Bontkes et al. (1999) | anti-HPV16 (IgG/A) | |
| Marais et al. (2000,2009) | anti-HPV16 (IgG/A) | |
| Elfgren et al. (1996) | anti-HPV16 (IgA) | |
| Bierl et al. (2005) | anti-HPV16 (IgG/A) | |
| Sasagawa et al. (2003) | anti-HPV16/18/31/45 (IgA/G) | |
| Gonçalves et al. (2016) | anti-HPV 16/18 (IgG/A) | |
| Ferreira Costa et al. (2018) | anti-HPV VLP (IgG/A) | |
| VLP-based multiplex immunoassay | Scherpenisse et al. (2013) | anti-HPV16/18/31/33/45/52/58 (IgG/A) |
| Oligopeptide ELISA | ||
| Synthetic peptide based | Snyder et al. (1991) | anti-HPV16 L1/E4 |
| Dillner et al. (1993) | anti-HPV16 L1/L2/E2/E7 (IgA/G) | |
| Dreyfus et al. (1995) | anti-HPV16 E2 (IgG/A) | |
| Elfgren et al. (1996) | anti-HPV16 E2/E7/L1/L2; HPV6 L1; HPV16/18 peptide 245 (IgA/G) | |
| Veress et al. (1994) | anti-HPV16 E2/E7/L1/L2 HPV11 L2 (sIgA) | |
| Rocha-Zavaleta et al. (2004) | anti-HPV16 L1 (IgA) | |
| Nguyen et al. (2005) | anti-HPV16 E7 (IgG/A) | |
| Tjiong et al. (2001) | anti-HPV16/18 E6/E7 (IgG) | |
| Wang et al. (1996) | anti-HPV16/18/33 L1 (IgA) | |
| Snowhite et al. (2002) | anti-HPV6/11/16/31/45 L1 (IgG/A) | |
| Onda et al. (2003) | anti-HPV16 L1 (IgA) | |
| Purified BPV-ELISA | Dillner et al. (1989;1993) | anti-PV (IgA/G) |
| Competitive Luminex immunoassay | ||
| HPV16 luminescence immunoassay (LIA) | Hagensee et al. (2000) | anti-HPV16 (IgG/(s)IgA) |
| Other | ||
| Radioactive immunoprecipitation assay (RIPA) | Tjiong et al. (2000) | anti-HPV16 E7 (IgG) |
| Inhibition assay, using HPV16 VLP and heparan sulfate proteoglycan-coated plates and pseudo infection systems, using HPV16 pseudovirions | Lopez et al. (2008) | anti-HPV16 (IgG/A) |
| Western blotting using HPV16 L1 protein from VLP16 (Kim et al., 2010) | Ekalaksananan et al. (2014) | anti-HPV16 L1 (IgG/A) |
Abbreviations: SEAP-NA, Secreted Alkaline Phosphatase Neutralization Assay; PBNA, Pseudovirion-based Neutralization Assay; VLP, virus-like particles; BPV, Bovine papillomavirus; RIPA, Radioactive immunoprecipitation assay.